Active — Not RecruitingPhase 4

Lorcaserin in Obesity: Identification of CNS Targets Using fMRI

United States40 participantsStarted 2014-10

Plain-language summary

The purpose of this protocol is to investigate, using functional magnetic resonance imaging (fMRI), the effect of treatment with lorcaserin on centers of the brain that control appetite and food intake, as well as lorcaserin's downstream metabolic effects.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Subjects using any other weight loss products (orlistat, phentermine, topiramate, fenfluramine, dexfenfluramine, amphetamines, GLP-1 agonists) or use within 3 months.
✕. Women who are breastfeeding, pregnant, or wanting to become pregnant.
✕. Women using IUD (intrauterine device)
✕. Any change in the dosage of hormonal contraceptive medications (birth control pills, implanon). Subjects should remain on same medication/ same dose during the time of the entire study.
✕. Moderate (creatinine clearance of 30-59 ml/min) and severe renal impairment (creatinine clearance below 30 ml/min) and end-stage renal disease
✕. Moderate, or severe hepatic impairment
✕. Hypersensitivity to the active substance or any of the excipients in lorcaserin
✕. Congestive heart failure and/or pulmonary hypertension

What they're measuring

fMRI (Functional changes in the brain)

Timeframe: 28 days

Trial details

NCT IDNCT02400359

SponsorBeth Israel Deaconess Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-06

View on ClinicalTrials.gov More Obesity trials